Advanced Refractive reaches milestone in macular degeneration treatment

By Elaine Rigoli

Tampa, Fla., Aug. 17 - Advanced Refractive Technologies, Inc., with its wholly owned subsidiary Ocular Therapeutics, Inc., said it has reached an important early milestone in its development of a treatment for age related macular degeneration (AMD).

Completion of this phase of the manufacturing process for LD22-4 has occurred and preclinical testing will be started shortly, according to a company news release.

Production of recombinant LD22-4 has proven to be efficient and economical, employing Food and Drug Administration-approved protocols suitable for preparing the compound for future clinical tests.

The ability to produce the LD22-4 at these levels, appropriate for pharmaceutical distribution at low cost, is one of the significant advantages of LD22-4 when compared to competing therapies, the release said.

Advanced Refractive is an ophthalmology development company in San Clemente, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.